Department of Medical Microbiology, Galway University Hospitals, Galway, Ireland.
BMC Infect Dis. 2012 May 15;12:116. doi: 10.1186/1471-2334-12-116.
Extended spectrum β-lactamase (ESBL) producing Enterobacteriaceae infections are associated with delayed initiation of appropriate treatment, poor outcomes and increased hospital stay and expense. Although initially associated with healthcare settings, more recent international reports have shown increasing isolation of ESBLs in the community. Both hospital and community ESBL epidemiology in Ireland are poorly defined.
This report describes clinical and laboratory data from three hospitals over 4.5 years. All significant isolates of Enterobacteriaceae were subjected to standardized antimicrobial susceptibility testing and screening for ESBL production. Available patient data from hospital databases were reviewed.
The database included 974 ESBL producing organisms from 464 patients. Urine and blood isolates represented 84% and 3% of isolates respectively. E. coli predominated (90.9%) followed by K. pneumoniae (5.6%). The majority of patients (n = 246, 53.0%) had been admitted to at least one of the study hospitals in the year prior to first isolation of ESBL. The overall 30-day all-cause mortality from the date of culture positivity was 9.7% and the 1 year mortality was 61.4%. A Cox regression analysis showed age over 60, male gender and previous hospital admissions were significant risk factors for death within 30 days of ESBL isolation. Numbers of ESBL-producing E. coli isolated from urine and blood cultures increased during the study. Urine isolates were more susceptible than blood isolates. Co-resistance to other classes of antimicrobial agents was more common in ESBL producers from residents of long stay facilities (LSF) compared with hospital inpatients who lived at home.
This work demonstrates a progressively increasing prevalence of ESBL Enterobacteriaceae in hospital, LSF and community specimens in a defined catchment area over a long time period . These results will improve clinician awareness of this problem and guide the development of empiric antimicrobial regimens for community acquired bloodstream and urinary tract infections.
产超广谱β-内酰胺酶(ESBL)的肠杆菌科感染与治疗开始延迟、不良结局以及住院时间延长和费用增加有关。虽然最初与医疗机构有关,但最近的国际报告显示,社区中 ESBL 的分离率不断增加。爱尔兰的医院和社区 ESBL 流行病学情况定义较差。
本报告描述了 4.5 年来 3 家医院的临床和实验室数据。对所有重要的肠杆菌科分离株进行标准化的抗菌药敏试验和 ESBL 产生筛选。对医院数据库中的可用患者数据进行了回顾。
该数据库包括 464 名患者的 974 株产 ESBL 菌。尿液和血液分离株分别占分离株的 84%和 3%。大肠杆菌占主导地位(90.9%),其次是肺炎克雷伯菌(5.6%)。大多数患者(n=246,53.0%)在首次分离出 ESBL 前一年曾至少在其中一家研究医院住院。从培养阳性日期开始,30 天内全因死亡率为 9.7%,1 年死亡率为 61.4%。Cox 回归分析显示,年龄大于 60 岁、男性和既往住院是 ESBL 分离后 30 天内死亡的显著危险因素。在研究期间,从尿液和血液培养中分离出的产 ESBL 大肠杆菌数量有所增加。尿液分离株比血液分离株更敏感。与住在家里的医院住院患者相比,长期居住设施(LSF)居民中的 ESBL 生产者对其他类别的抗菌药物的共同耐药更为常见。
这项工作表明,在一个特定的地理区域,在很长一段时间内,医院、LSF 和社区标本中 ESBL 肠杆菌科的流行率呈逐渐上升趋势。这些结果将提高临床医生对这一问题的认识,并指导经验性抗菌治疗方案的制定,用于社区获得性血流感染和尿路感染。